<DOC>
	<DOCNO>NCT00366938</DOCNO>
	<brief_summary>This study investigate efficacy safety lumiracoxib patient primary knee osteoarthritis ( OA ) .</brief_summary>
	<brief_title>Efficacy Safety Lumiracoxib Patients With Knee Osteoarthritis ( OA ) .</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Primary osteoarthritis knee ( confirmed American College Rheumatology [ ACR ] criterion ) . Requirement regular nonsteroidal antiinflammatory drug ( NSAID ) therapy . Evidence active gastrointestinal ulceration within 12 month prior screen visit history active gastrointestinal bleeding within previous 5 year . Known hypersensitivity analgesic , antipyretic , NSAIDS ( include celecoxib ) . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Osteoarthritis , lumiracoxib , celecoxib , Cox-2</keyword>
</DOC>